Edwards Lifesciences (EW) Long-Term Debt Issuances (2009 - 2021)

Edwards Lifesciences has reported Long-Term Debt Issuances for 11 years, with the latest figure at -$8.8 million in Q3 2021.

• For the quarter ending Q3 2021, Long-Term Debt Issuances fell 617.65% year-over-year to -$8.8 million; the trailing twelve-month figure through Jun 2022 stood at -$8.8 million (down 144.9% YoY), and the FY2021 full-year result was $5.2 million, down 67.9% from the prior year.
• Long-Term Debt Issuances for Q3 2021 stood at -$8.8 million, down from $9.5 million in the prior quarter.
• The five-year high for Long-Term Debt Issuances was $608.0 million in Q2 2017, with the low at -$8.8 million in Q3 2021.
• Average Long-Term Debt Issuances over 5 years is $86.4 million, with a median of $4.5 million recorded in 2021.
• Year-over-year, Long-Term Debt Issuances jumped 9706.45% in 2017 and slumped 617.65% in 2021.
• Tracing EW's Long-Term Debt Issuances over 5 years: stood at $5.4 million in 2017, then tumbled by 70.37% to $1.6 million in 2018, then soared by 331.25% to $6.9 million in 2019, then sank by 43.48% to $3.9 million in 2020, then slumped by 325.64% to -$8.8 million in 2021.
• The last three Long-Term Debt Issuances figures came in at -$8.8 million (Q3 2021), $9.5 million (Q2 2021), and $4.5 million (Q1 2021), per Business Quant data.

Peer Comparison